Shilpa Medicare Hits Record Revenue & EBITDA on Strong Formulation Growth

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Shilpa Medicare Hits Record Revenue & EBITDA on Strong Formulation Growth
Overview

Shilpa Medicare Limited has achieved its highest-ever quarterly revenue and EBITDA in Q3 FY26, with revenue surging 28% YoY to INR 411 crores and EBITDA jumping 41% YoY to INR 115 crores. EBITDA margins expanded to 28%. The company's formulation business, particularly in Europe, showed over 100% YoY growth, with base formulations up 104% QoQ. Management indicated a shift towards execution and ROCE maximization, with adjusted ROCE nearing 17% for the 9-month period. Net debt remains manageable at INR 625 crores.

📉 The Financial Deep Dive

Shilpa Medicare Limited announced its Q3 and 9 Months FY26 results, marking a significant operational and financial milestone with its highest-ever quarterly revenue and EBITDA.

  • The Numbers: Total revenue for the quarter reached an all-time high of INR 411 crores, reflecting a robust 28% year-on-year growth. For the nine-month period ending December 31, 2025, revenue stood at INR 1,110 crores, a healthy 14% increase over the previous year.

  • Profitability & Margins: The company posted a record quarterly EBITDA of INR 115 crores, a substantial 41% jump from INR 82 crores in Q3 FY25. This surge drove EBITDA margins higher, expanding to 28% from 26% in the prior year's comparable quarter. For the nine-month period, margins were even stronger at 29%, up from 26% YoY.

  • Exceptional Items & PAT: A pre-tax exceptional item of INR 13 crores was recognized due to changes in India's Labour Code. Adjusting for this, the Profit After Tax (PAT) for the quarter was INR 55 crores. For the 9-month period, adjusted PAT stood at INR 146 crores, nearly doubling the full-year PAT of FY25.

  • Investment & Debt: Capital expenditure (CapEx) during the quarter was INR 87 crores, predominantly funded by internal accruals, which also contributed to a reduced interest outgo. Net debt as of December 31, 2025, was INR 625 crores, maintaining a low debt-to-equity ratio of approximately 0.25-0.26.

📊 Segmental Performance & Outlook

  • API Business: This segment (including captive consumption) posted revenue of INR 243 crores for the quarter, growing 11% YoY.

  • Formulation Business: This segment was the star performer, reporting revenues of INR 177 crores for the quarter, a remarkable 50% increase YoY. Excluding licensing income, the base formulation business witnessed an exceptional 104% quarter-on-quarter increase and an 83% rise for the 9-month period. The European Formulation business also delivered an impressive over 100% revenue growth year-on-year.

  • Pipeline & Future Growth: Key developments include the successful launch of NorUDCA, which has exceeded expectations and built a healthy order book. Marketing authorization for the first transdermal patch, Rotigotine, was secured for launch in FY27, with a US filing planned for Q4 FY26. Phase III studies for Biologics product Aflibercept are progressing for an H1 FY27 submission. An Advanced Drug Conjugate (ADC) manufacturing GMP facility is set to be commissioned in Q4 FY26.

  • Management Focus: Management emphasized the completion of the heavy investment phase, with a strategic pivot towards execution, scaling, and maximizing Return on Capital Employed (ROCE). The company highlighted an improved ROCE profile, with adjusted ROCE (excluding high-growth potential businesses) climbing from a low of 3.5% in FY23 to over 17% in the first 9 months of FY26.

🚩 Risks & The Forward View

While the results are strong, investors will watch the execution of new product launches, particularly Rotigotine in the US and the Aflibercept submission. The commissioning of the ADC facility is another key event to monitor. The company's stated focus on ROCE and scaling operations suggests a period of sustained operational efficiency and profitability.

Impact

Rating: 8/10. This news is highly significant for Shilpa Medicare investors, indicating a strong turnaround and positive momentum. The record results, margin expansion, and robust formulation growth, coupled with a clear strategic focus on ROCE and de-risked investment phase, paint a very encouraging picture. The low debt and improving financial health further bolster confidence.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.